Drugs · Entity Annotation Prototype (beta)

7articles mentioning drugs

22drug mentions

1distinct drugs extracted

0%of mentions human-reviewed

Active filtersEntity: mSTAR1302 ×

mSTAR1302

This drug is selected. Its supporting articles are shown below.

mSTAR13027

Articles mentioning mSTAR1302

7 articles · page 1 of 1

629 Triple combination therapy with a TCR Vb-directed bifunctional molecule, cisplatin and anti-PD-1 in immune checkpoint blockade-refractory head and neck murine tumor models

jitc · abstract · 2025-11-04 · 6 matching annotations

95.3%

STAR0602 mSTAR1302 cisplatin head and neck squamous cell carcinoma (HNSCC)NIH Intramural Animal Care and Use Committee carcinogen-associated HNSCC C57BL/6 mice

…sions These findings provide a rationale for the combination of STAR0602 and SOC therapy in the clinical setting for patients with recur…

Combination of a novel TCR Vβ chain-directed selective T cell activator with standard of care therapy for head and neck cancer improves antitumor responses and promotes regression of checkpoint-refractory tumor models

jitc · abstract · 2025-10-28 · 6 matching annotations

95.1%

STAR0602 cisplatin mSTAR1302 head and neck squamous cell carcinoma (HNSCC)

…usion These findings provide a rationale for the combination of STAR0602 and SOC therapy in the clinical setting for patients with recur…

916 A novel anti-TCR Vb targeted bispecific antibody in combination with a poly ADP-ribose polymerase inhibitor (PARPi) enhances anti-tumor immune response in prostate cancer models

jitc · abstract · 2025-11-04 · 4 matching annotations

90.8%

Olaparib STAR0602 mSTAR1302 IL-2 mCRPC prostate cancer NCT05592626 TRAMP-C2

…uppression of TRAMP-C2 and RM-1 tumors compared to mSTAR1302 or Olaparib monotherapies. In both models, combination therapy resulted in …

PARP inhibition combined with a T-cell receptor β chain-directed antibody fusion molecule drives polyclonal antitumor immunity and tumor regression

jitc · abstract · 2026-07-01 · 2 matching annotations

92.5%

olaparib STAR0602 mSTAR1302 mSTAR1302-mediated Metastatic castration-resistant prostate cancer (mCRPC)mCRPC NCT05592626

…ate cancer.Methods The antitumor activity of the PARP inhibitor olaparib combined with mSTAR1302, the murine surrogate of STAR0602, was …

663 Epigenetic modulation synergizes with TCRβ-targeted IL-2 to yield CD8+ T cell dependent, MHC-I independent tumor control via an antibody associated mechanism

jitc · abstract · 2025-11-04 · 2 matching annotations

85.5%

Entinostat STAR0602 mSTAR1302 solid malignancies human cancers EMT6 MC38

….2/13.3, in combination with the class I HDAC inhibitor (HDACi) Entinostat, an epigenetic modulator that enhances tumor immune cell recogn…

625 Docetaxel enhances the anti-tumor activity of a novel bi-functional TCR activating molecule in breast and prostate cancer models

jitc · abstract · 2025-11-04 · 1 matching annotations

76.4%

docetaxel docetaxel-induced STAR0602 mSTAR1302 4T1 TRAMP-C2

…AR1302 (1mg/kg) was administered once per week for 3 weeks, and docetaxel (500µg) in 3 doses, every other day, for 1 week. Tumors, spleen…

660 A novel TCRβ-directed IL-2 fusion molecule promotes memory CD8+ T cells with self-renewing properties in tumor ecosystems, further expanded by HDAC inhibition to elicit effective tumor suppression